In this study, we combined the “occupancy-driven modality” of TKIs with the “event-driven modality” of bifunctional molecules to achieve dual inhibition of EGFR with TKI-based PhosTAC, which reveals differential downstream effects.
I’m thrilled to share our recent work on dual inhition of EGFR with PhosTAC. Congrats to the team @POHANCHEN9, Wenxue, @siszheng, @JacquesSaarbach, Ines and John. And we are deeply grateful for the great mentorship from @Yanshen73854711 and @CraigMCrews!
https://t.co/zJIl04JJZm
Excited to share our Tau PhosTAC paper on @J_A_C_S . PhosTAC provides a new modality for neurodegenerative diseases treatment. Many thanks to @CraigMCrews, and the awesome team Po-Han Chen, Wenxue Li, @ToddDouglasPhD , John @Yanshen73854711 🎉#PhosTAC
https://t.co/JIRlDIm8Fp
Ever wanted to dephosphorylate just a single phosphoprotein instead of blocking all downstream kinase substrates with a kinase inhibitor? Check our new PoC paper describing PhosTACs that recruit phosphatases to selected phosphoproteins. #PhosTACs https://t.co/hjZ37e6b6R